Morgan Stanley Adjusts AbbVie Price Target to $211 From $196
AbbVie Analyst Ratings
Wells Fargo Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $200
J.P. Morgan Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $210
Barclays Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $200
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,125
Buy Rating Affirmed for AbbVie Amidst Strong Financials and Strategic Management
Barclays Reaffirms Their Buy Rating on AbbVie (ABBV)
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Piper Sandler Adjusts Price Target on AbbVie to $196 From $190
HC Wainwright Adjusts Price Target on United Therapeutics to $400 From $300, Maintains Buy Rating
Cantor Fitzgerald Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $885
H.C. Wainwright Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $400
United Therapeutics Analyst Ratings
Eli Lilly and Co Analyst Ratings
Wolfe Research Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,117
Wolfe Research Adjusts Eli Lilly's Price Target to $1,117 From $909
Buy Rating Affirmed: Sangamo's Hemophilia A Gene Therapy Poised for Success With Pfizer Partnership
Daiwa Securities Adjusts Price Target on Abbott Laboratories to $120 From $125
Stifel Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $7